Please login to the form below

Not currently logged in
Email:
Password:

Mvasi

This page shows the latest Mvasi news and features for those working in and with pharma, biotech and healthcare.

Roche eyes September FDA verdict for triple NSCLC therapy

Roche eyes September FDA verdict for triple NSCLC therapy

Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.

Latest news

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    year. Avastin (bevacizumab), Roche’s biggest-selling cancer drug, will imminently face some stiff competition in the EU from Amgen and Allergan’s recently licenced biosimilar Mvasi - which became the first

  • Amgen and Allergan win first EU approval for Avastin biosimilar Amgen and Allergan win first EU approval for Avastin biosimilar

    Amgen and Allergan win first EU approval for Avastin biosimilar. Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers. ... The approval was based on data showing Mvasi and beveacizumab are highly similar, with no clinically

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    cancer antibody after Amgen and Allergan got a green light for their Mvasi biosimilar of Roche’s Avastin (bevacizumab) in September.

  • Amgen's Mvasi is first FDA-approved cancer biosimilar Amgen's Mvasi is first FDA-approved cancer biosimilar

    Amgen's Mvasi is first FDA-approved cancer biosimilar. Offers prospect of lower-cost alternative to Roche's Avastin. ... Mvasi reaches the market ahead of rival Avastin biosimilars from Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan that

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics